Penumbra Inc (PEN)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $12.65B
Last updated: Nov 17, 2026 at 4:20 PM ET
Penumbra Inc (PEN) Stock Chart
Penumbra (PEN) has a latest price of $319.13 on Nov 17, 2026, 11.9% below its 52-week high of $362.41. Its price rose 13.9% over the past 12 months. The month-end price rose 383.6% over the 10 years through Oct 2026, a compound annual rate of 17.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $358.17 in Jan 2026 and its lowest $61.90 in Nov 2016, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart PEN with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for PEN.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 2.4%, and over 6 months it fell 2.3%. The month-end price rose 66.9% over the 3 years through Oct 2026, a compound annual rate of 18.6%.
| Period | Change |
|---|---|
| 1 month | -1.0% |
| 3 months | -2.4% |
| 6 months | -2.3% |
| 12 months | +13.9% |
| 12 months, with dividends | +13.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +66.9% | +18.6% |
| 5 years | +15.3% | +2.9% |
| 10 years | +383.6% | +17.1% |
Price by Year
Its best calendar year was 2021, when the price rose 64.2%, and its weakest was 2022, when it fell 22.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $318.95 | +2.6% |
| 2025 | $310.91 | +30.9% |
| 2024 | $237.48 | -5.6% |
| 2023 | $251.54 | +13.1% |
| 2022 | $222.46 | -22.6% |
| 2021 | $287.32 | +64.2% |
| 2020 | $175.00 | +6.5% |
| 2019 | $164.27 | +34.4% |
| 2018 | $122.20 | +29.9% |
| 2017 | $94.10 | +47.5% |
Trading Range
The price is 0.3% below its 50-day average of $320.11 and 1.9% below its 200-day average of $325.33.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $319.13 | |
| 52-week high | $362.41 | -11.9% |
| 52-week low | $276.72 | +15.3% |
| 50-day average | $320.11 | -0.3% |
| 200-day average | $325.33 | -1.9% |
Price Risk
Over 3 years, its largest fall from a peak was 40.1%.
| Measure | Value |
|---|---|
| 1-year beta | 0.19 |
| Largest fall, 1 year | -12.2% |
| Largest fall, 3 years | -40.1% |
Valuation
Penumbra traded at 81.0x earnings at the end of 2025, against a 5-year median of 90.7x.
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About PEN
What is PEN's 1-year price change?
Penumbra's price rose 13.9% over the past 12 months. With dividends included, the 12-month total return was 13.9%.
What is PEN's 5-year price change?
Penumbra's month-end price rose 15.3% over the 5 years through Oct 2026, a compound annual rate of 2.9%. These figures leave out dividends.
What is PEN's 52-week high and low?
Penumbra's 52-week high is $362.41 and its 52-week low is $276.72. Its latest price of $319.13 on Nov 17, 2026 is 11.9% below the high.
What is PEN's beta?
Penumbra's 1-year beta against the S&P 500 is 0.19, so its price has shown little link to the market's moves over the past year. Its largest fall from a peak over the past year was 12.2%.
Is the PEN chart free?
Yes. Advanced Charting for PEN is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
PEN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts